China Bio Energy Reports Fourth Quarter and Record 2008 Financi...(208 5476256 Loans payable - ...)

Date:3/23/2009

208 5,476,256 Loans payable - Non-current -- 33,655 TOTAL LIABILITIES 10,795,208 5,509,911 STOCKHOLDERS' EQUITY Preferred stock, $.001 par value; authorized shares 10,000,000; issued and outstanding 3,465,753 and 1,000,000 shares at December 31, 2008 and 2007, respectively 3,465 1,000 Common stock, $.0001 par value; authorized shares 79,000,000; issued and outstanding 27,169,091 and 25,454,545 shares at December 31, 2008 and 2007, respectively 2,716 2,545 Additional paid in capital 44,434,250 19,611,938 Statutory reserve 4,920,114 2,051,030 Accumulated other comprehensive income 5,337,003 2,319,732 Retained earnings 29,201,661 14,209,392 Total stockholders' equity 83,899,209 38,195,637 TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $94,694,417 $43,705,548 CHINA BIO ENERGY HOLDING GROUP CO., LTD. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF INCOME AND OTHER COMPREHENSIVE INCOME For The Year Ended December 31, 2008 December 31, 2007 Sales $216,506,969 $87,104,187 Cost of goods sold 185,858,502 77,006,690 Gross profit 30,648,467 10,097,497 Selling, general and administrative expenses 1,997,818 1,686,760 Incom
'/>"/>

SOURCE China Bio Energy Holdings Group Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
Related biology technology :

1. aTyr Pharma to Present at ChinaBio(R) Investor Forum in Hong Kong
2. Niusule Biotech Corp. Formally Establishes a New Venture to Import and Sell Health Foods in the Peoples Republic of China
3. China-Biotics, Inc. Appoints New Chief Financial Officer
4. China Medical Technologies Senior Management Purchased Company Shares
5. China Bio-Immunity Corporation - Rabies Vaccine Recall
6. China Medicine to Participate in 2009 Natural Products Expo West Trade Show
7. China Sky One Medical, Inc. Signs Exclusive Distribution Agreement with Shaanxi Buchang Group for Naftopidil Dispersible Tablets
8. Frontage Laboratories Continues to Grow Its China Business and Add Corporate Financial, Regulatory and Clinical Pharmacology Talent
9. Dow AgroSciences, China National Rice Research Institute Announce Collaboration on Rice Research
10. China Biologic Products High-Purity Human Albumin Research and Development Project to be Listed in the National Torch Plan
11. OriGene Technologies, Inc. Establishes High Throughput Monoclonal Antibody Production Outsourcing Center in China